Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13434570 | 0.87 | REN (0.61) | RENHTR1AADRA1DHTR2AADRA1A | |
| SCHEMBL13434566 | 0.84 | REN (0.58) | RENHTR1AADRA1DHTR2AADRA1A | |
| SCHEMBL13434560 | 0.83 | REN (0.60) | RENHTR1AADRA1DHTR2AADRA1A | |
| SCHEMBL13434571 | 0.83 | REN (0.58) | RENHTR1AADRA1DHTR2AADRA1A | |
| Hydrochloric Acid SCHEMBL3487518 | 0.83 | REN (0.59) | RENHTR1AADRA1DHTR2AADRA1A | |
| SCHEMBL13434568 | 0.83 | REN (0.57) | RENHTR1AADRA1DHTR2AADRA1A | |
| SCHEMBL3487708 | 0.82 | REN (0.51) | RENHTR1AADRA1DHTR2AADRA1A | |
| SCHEMBL13434525 | 0.82 | REN (0.59) | RENHTR1AADRA1DHTR2AADRA1A | |
| SCHEMBL13434572 | 0.82 | REN (0.56) | RENHTR1AADRA1DHTR2AADRA1A | |
| SCHEMBL13434063 | 0.82 | REN (0.59) | RENHTR1AADRA1DHTR2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | REN 1/4885HTR1A 993/4885ADRA1D 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.